Paykel Neela

SEC source: 0001209191-22-057386 · doc4.xml · nonDerivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,172

F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted on March 29, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement.

SEC source: 0001209191-22-055109 · doc4.xml · derivative · entry 6

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,250

Underlying: Class A Common Stock · 98,250 shares

Expires 2031-04-27

F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 30,702 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 30,702 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 30,702 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

SEC source: 0001209191-22-055109 · doc4.xml · derivative · entry 5

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 98,250 shares

Expires 2031-04-27

F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 30,702 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 30,702 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 30,702 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

SEC source: 0001209191-22-055109 · doc4.xml · derivative · entry 4

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Class A Common Stock · 85,000 shares

Expires 2032-02-09

F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001209191-22-055109 · doc4.xml · derivative · entry 3

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 85,000 shares

Expires 2032-02-09

F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001209191-22-055109 · doc4.xml · derivative · entry 2

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,750

Underlying: Class A Common Stock · 71,750 shares

Expires 2032-02-09

F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 25,411 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 25,411 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 25,411 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

SEC source: 0001209191-22-055109 · doc4.xml · derivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 71,750 shares

Expires 2032-02-09

F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 25,411 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 25,411 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 25,411 shares vested and the remainder of the options vesting in equal monthly installments, subject to Ms. Paykel's continued service on each vesting date.

SEC source: 0001209191-22-046104 · doc4.xml · nonDerivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,067

F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted on March 29, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement.

SEC source: 0001209191-22-041106 · doc4.xml · nonDerivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,958

F1 · shares: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted on March 29, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement.

SEC source: 0001104659-22-041201 · tm2211004-4_4seq1.xml · nonDerivative · entry 2

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,500

F2 · shares: The shares underlying this RSU vest as to 25% on March 20, 2023, and the remainder in equal quarterly installments at the mid-point of each calendar quarter over the following three years, beginning on May 15, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001104659-22-041201 · tm2211004-4_4seq1.xml · nonDerivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

F1 · shares: The shares underlying this restricted stock unit ("RSU") vest as to 25% on May 1, 2022, and the remainder in equal quarterly installments at the mid-point of each calendar quarter over the following three years beginning May 15, 2022; provided that any vesting of the award will be delayed until July 1, 2022, and the number of RSUs vesting on the first scheduled vesting date following July 1, 2022 will also include any delayed vesting RSUs, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001104659-22-020802 · tm226447-4_4seq1.xml · derivative · entry 2

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Class A Common Stock · 85,000 shares

Expires 2032-02-09

F2 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001104659-22-020802 · tm226447-4_4seq1.xml · derivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,750

Underlying: Class A Common Stock · 71,750 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on May 1, 2022, and 2.083% at the end of each month thereafter beginning on June 30, 2022, subject to Ms. Paykel's continued service through the applicable vesting date.

SEC source: 0001104659-21-153333 · tm2135698-16_4seq1.xml · derivative · entry 1

Paykel Neela · CIK 0001894593 · Gen Counsel & Corp Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,250

Underlying: Class A Common Stock · 98,250 shares

Expires 2031-04-27

F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc.,

F3 · price: a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), the option was received in the Mergers in exchange for a stock option to acquire 300,000 shares of Hyperfine common stock for $1.07.

F1 · derivative.exercise_date: The shares underlying this option vested as to 25% on June 30, 2022, with the remainder of the options vesting in equal monthly installments over the following three years, subject to Ms. Paykel's continued service through the applicable vesting date.